Impact of TNF on Oncolytic Virotherapy

TNF 对溶瘤病毒治疗的影响

基本信息

项目摘要

Project Summary: Oncolytic virotherapy (OV) represents a novel method to treat a variety of solid tumors by inducing anti-tumor immune responses. While this therapy has been extremely efficacious in a wide variety of preclinical models, translating these successes into human patients has proven challenging. It has recently become clear that one of the major reasons for these failures is the existence of immune-regulatory mechanisms which dampen the efficacy of virally induced anti-tumor immunity. However, the exact nature of these regulatory pathways remains unclear. Our lab has previously developed a novel oncolytic MYXV which expresses a soluble PD1 inhibitor and an IL12 fusion protein (vPD1/IL12). This construct is highly effective at treating disseminated disease, however, ~50% of tumor models remain at least partially non-responsive and viral treatment is associated with the development of immune-related adverse events. In our follow-up studies into the mechanisms mediating the efficacy of vPD1/IL12 we have observed that the virus induces high levels of TNF during therapy. Strikingly, both genetic elimination or antibody-based blockade of this TNF results in a significant INCREASE in therapeutic efficacy as well as a significant REDUCTION in toxicity. To our knowledge, no other studies have demonstrated a positive impact of TNF blockade on OV and therefore both the mechanism(s) involved as well as how to leverage this finding into improved clinical outcomes remains unclear. We therefore put forth the current proposal which contains three specific aims designed to build off of our exciting preliminary data by: identifying the mechanism through which TNF restricts OV efficacy, understanding how TNF mediates OV- induced toxicities, and determining clinically applicable methods to apply TNF-blockade during OV. This work will advance not only the clinical use of our existing vPD1/IL12 virus, but also improve our understanding of the basic mechanisms involved in successful OV.
项目概述:溶瘤病毒疗法(OV)是一种通过以下方式治疗各种实体瘤的新方法: 诱导抗肿瘤免疫应答。虽然这种疗法在各种各样的疾病中非常有效, 临床前模型,将这些成功转化为人类患者已被证明具有挑战性。它最近 很明显,这些失败的主要原因之一是免疫调节的存在。 抑制病毒诱导的抗肿瘤免疫效力的机制。然而, 这些调控途径仍不清楚。 我们的实验室先前已经开发了一种新的溶瘤MYXV,它表达可溶性PD 1抑制剂和一种抗肿瘤药物。 IL 12融合蛋白(vPD 1/IL 12)。然而,这种构建体在治疗播散性疾病方面非常有效, 约50%的肿瘤模型至少部分保持无反应,病毒治疗与肿瘤的发生有关。 发生免疫相关不良事件。在我们的后续研究中, vPD 1/IL 12的功效我们已经观察到病毒在治疗过程中诱导高水平的TNF。引人注目的是, 这种TNF的基因消除或基于抗体的阻断均导致 治疗效果以及毒性的显著降低。据我们所知,没有其他研究 证实了TNF阻断对OV的积极影响,因此这两种机制也都涉及 因为如何利用这一发现来改善临床结果仍不清楚。我曾为他们做过一件事。 目前的提案包含三个具体目标,旨在通过以下方式建立我们令人兴奋的初步数据: 确定TNF限制OV疗效的机制,了解TNF如何介导OV-1, 诱导的毒性,并确定在OV期间应用TNF阻断的临床适用方法。这项工作 不仅将推进我们现有的vPD 1/IL 12病毒的临床应用,还将提高我们对vPD 1/IL 12病毒的认识。 成功OV的基本机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eric Carter Bartee其他文献

Eric Carter Bartee的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eric Carter Bartee', 18)}}的其他基金

Impact of extracellular potassium on oncolytic therapy
细胞外钾对溶瘤治疗的影响
  • 批准号:
    10347566
  • 财政年份:
    2022
  • 资助金额:
    $ 43.82万
  • 项目类别:
Impact of extracellular potassium on oncolytic therapy
细胞外钾对溶瘤治疗的影响
  • 批准号:
    10542780
  • 财政年份:
    2022
  • 资助金额:
    $ 43.82万
  • 项目类别:
Impact of envelope proteins on poxviral pathogenesis
包膜蛋白对痘病毒发病机制的影响
  • 批准号:
    9092002
  • 财政年份:
    2016
  • 资助金额:
    $ 43.82万
  • 项目类别:
Impact of envelope proteins on poxviral pathogenesis
包膜蛋白对痘病毒发病机制的影响
  • 批准号:
    9335261
  • 财政年份:
    2016
  • 资助金额:
    $ 43.82万
  • 项目类别:
Treatment of multiple myeloma using oncolytic myxoma virus
使用溶瘤粘液瘤病毒治疗多发性骨髓瘤
  • 批准号:
    9187445
  • 财政年份:
    2015
  • 资助金额:
    $ 43.82万
  • 项目类别:
Treatment of transplanted and established multiple myeloma using oncolytic myxoma
使用溶瘤粘液瘤治疗移植和建立的多发性骨髓瘤
  • 批准号:
    8300521
  • 财政年份:
    2013
  • 资助金额:
    $ 43.82万
  • 项目类别:
Treatment of transplanted and established multiple myeloma using oncolytic myxoma
使用溶瘤粘液瘤治疗移植和建立的多发性骨髓瘤
  • 批准号:
    8627540
  • 财政年份:
    2013
  • 资助金额:
    $ 43.82万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 43.82万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 43.82万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 43.82万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 43.82万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了